NCT Number: NCT02812784
Can Nephrocheck™ Predict the Reversibility of Early, Acute Kidney Injury During Septic Shock?
Patients with septic shock in the intensive care unit have an elevated risk of developing acute kidney injury (AKI).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
CHU Amiens, Amiens, France
About this study
Patients with septic shock in the intensive care unit have an elevated risk of developing acute kidney injury (AKI). AKI is an independent factor for mortality. Interventions that limit the worsening of renal function might have an impact on the mortality rate in these patients. Given the absence of validated pharmacological treatments for limiting the progression of AKI or for accelerating recovery from AKI, early intervention and the restoration of the glomerular filtration rate (GFR) in this context of hemodynamic change during the initial phase of septic shock might improve the patients' prognosis. One major challenge is therefore how to determine whether or not the AKI is reversible. The best-studied biomarkers (NGAL and KIM 1) have little discriminant power in septic patients because of their poor specificity or unsuitable kinetics for very early diagnosis. The combination of urine assays for tissue inhibitor of metalloproteinase 2 (TIMP2) and insulin-like growth factor binding protein 7 (IGFBP7) has shown good diagnostic performance for the very early detection of the risk of developing AKI in the following 12 hrs. Urine levels of these two markers specifically reflect damage to kidney tubules. Moreover, the levels appear to be strongly correlated with the severity of tubule damage. Thus, one can reasonably hypothesize that measurement of these markers in the very early stages of septic shock might determine the presence and severity of kidney tubule damage. A threshold (yet to be defined) would help to differentiate between (i) transient, non-severe injury and (ii) injury that is already too severe to be reversible.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age 18 or over
- Septic shock (according to Bone's criteria) within 4 hours of introduction of catecholamines
- AKI, characterized by a KDIGO score ≥ 1
- Social security coverage
Exclusion criteria
- AKI requiring emergency RRT (in the critical care physician's opinion).
- Anuria
- Stage 4-5 chronic kidney failure with a GFR below 30 ml/min.
- Rapidly progressing renal disorders (glomerulonephritis, HUS, blockage, etc.)
- Obstructive AKI
- Probable glomerular damage (nephritic syndrome, nephrotic syndrome, chronic glomerulonephritis)
- Pregnancy or breastfeeding
- Legal guardianship or lack of social security coverage.
- Cardiocirculatory arrest
- Life expectancy <48 hours.
- Child C cirrhosis
- Prior occurrence of AKI during the current hospital stay
- Transplantation
- Subject participating in another study with an exclusion period ongoing at the time of the pre-inclusion
Treatment and study plan
Primary outcomes
-
KDIGO classification
Time frame: 72 hours
predictive value of Nephrocheck™ with regard to the reversibility of AKI, defined as the recovery of normal renal function (KDIGO 0) in the 72 hours following inclusion
Sponsors and collaborators
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Other
Registry information
Acronym: AKI-CHECK
Important dates
- Study start
- 2015
- Primary completion
- 2019
- Study completion
- 2019
- First posted
- Jun 24, 2016
- Registry last updated
- Jun 12, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Dialyzing Wisely - Improving the Delivery of Acute Renal Replacement Therapy to Albertans
NCT05186636
Acute Kidney Injury, Acute Renal Injury
Calgary, Alberta, Canada
View Trial DetailsNovel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
NCT06483139
Acute Kidney Injury, Blood Protein Disorders
Boston, Massachusetts, United States
View Trial DetailsPredicting Worsening Acute Kidney Injury With a Water-Pill (Furosemide) Test and Blood Markers in Patients With Low Albumin
NCT07688733
Acute Kidney Injury, Blood Protein Disorders
Monterrey, Nuevo León, Mexico
View Trial DetailsMeasurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure
NCT02961478
Acute Kidney Injury, Acute Renal Failure
Angers, France
View Trial Details